

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HighTide Therapeutics, Inc.**

**君圣泰医药**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 2511)**

## **GRANTS OF OPTIONS AND AWARDS**

This announcement is made by the Company pursuant to Rules 17.06A, 17.06B and 17.06C of the Listing Rules.

The Board hereby announces that on September 1, 2026, the Company granted (i) 2,040,450 Options to 4 Grantees, and (ii) 306,749 Awards to 1 Grantee pursuant to the 2025 Share Incentive Plan (together, the “**Grant**”), representing approximately 0.30% and 0.05% of the total Shares in issue and outstanding (excluding the treasury Shares) as of the Grant Date, respectively.

The details of the Grant are as follows:

|                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Grant Date:</b>                            | September 1, 2026                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Number of the Options/Awards granted:</b>  | <p>(i) 2,040,450 Options, among which, 644,171 Options are granted to three Employee Participants and 1,396,279 Options are granted to Dr. Filip Surmont (“<b>Dr. Surmont</b>”).</p> <p>Dr. Surmont is the chief medical officer of the Group and is primarily responsible for overseeing and giving advice on the Company’s global medical strategy, clinical development and medical affairs, and accelerating the clinical progress and value enhancement of the Company’s core pipeline in the field of cardiovascular-kidney-metabolic (CKM) diseases.</p> <p>(ii) 306,749 Awards to one Employee Participant.</p> |
| <b>Exercise price of the Options granted:</b> | <p>HK\$3.154 per Share, representing the higher of:</p> <p>(i) the closing price of HK\$3.14 per Share as stated in the daily quotations sheets issued by the Stock Exchange on the Grant Date; and</p> <p>(ii) the average closing price of HK\$3.154 per Share as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the Grant Date.</p>                                                                                                                                                                                                             |

|                                                       |                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Purchase price of the Awards granted:</b>          | Nil                                                                                                                                                                                                                                                                                                                                                    |
| <b>Closing price of the Shares on the Grant Date:</b> | HK\$3.14 per Share                                                                                                                                                                                                                                                                                                                                     |
| <b>Exercise Period of the Options:</b>                | 10 years from the Grant Date                                                                                                                                                                                                                                                                                                                           |
| <b>Vesting period:</b>                                | <p>The Options and Awards granted shall vest as follows:</p> <p>(i) 20% of the Options and Awards shall vest on May 1, 2028;</p> <p>(ii) 30% of the Options and Awards shall vest on the third anniversary of the Grant Date; and</p> <p>(iii) the remaining 50% of the Options and Awards shall vest on the fourth anniversary of the Grant Date.</p> |
| <b>Performance target(s):</b>                         | <p>The vesting of each tranche of the Options and Awards is subject to satisfaction of the individual performance targets and the Company's annual performance targets for the relevant assessment year, as determined by the Board at its absolute discretion.</p>                                                                                    |

**Vesting proportion of each tranche = individual vesting coefficient × Company vesting coefficient**

| <b>Assessment standards</b>    | <b>Qualified or above</b>      | <b>Unqualified</b>                   |
|--------------------------------|--------------------------------|--------------------------------------|
| Individual vesting coefficient | 1                              | 0                                    |
| <b>Assessment standards</b>    | <b>Achievement rate ≥ 100%</b> | <b>Achievement rate &lt; 100%</b>    |
| Company vesting coefficient    | 1                              | Equal to the actual achievement rate |

**Clawback  
mechanism:**

In the event that:

- (a) a grantee ceases to be an eligible participant by reason of the termination of his/her employment with the Group or contractual engagement with the Group as a result of (i) negligence in performing, or refusal to perform, any major duties to the Group, or material violation of any code of conduct, rules, regulations, or policies of the Group, (ii) performance of any act or failure to perform any act in bad faith and to the detriment of the Group (economical or reputational), or (iii) dishonesty or commitment in an act of theft, embezzlement, fraud, or a breach of trust;
- (b) a grantee engages in serious misconduct or breaches the terms, including with respect to (i) any intentional misconduct or material breach of any labor contract (employment agreement), non-disclosure obligation, non-competition obligation, non-solicitation obligation or other agreement between the grantee and the Group or (ii) breach of a fiduciary duty, or commission of a crime (other than minor traffic violations or similar offenses), (iii) material violation of any laws or regulations;
- (c) a grantee has engaged in any act or omission to perform his/her duties in a manner detrimental to the reputation, business operation, assets, or market image of the Group; or
- (d) the award to the grantee will no longer be appropriate and aligned with the purpose of the 2025 Share Incentive Plan,

the Board or the Scheme Administrator may make a determination at its absolute discretion that: (a) any awards granted to that grantee but not yet vested and/or exercised (as the case may be) shall immediately lapse, (b) with respect to any award shares transferred to that grantee, the grantee shall be required to transfer back to the Company or its nominee (i) the equivalent number of shares, (ii) an amount in cash equal to the market value (as determined by the Board or the Scheme Administrator with reference to the quoted price on the Stock Exchange of such shares on any one of the following dates: (x) the date of grant, (y) the date of exercise or the vesting date of the relevant awards, or (z) the date of such clawback) of such shares, or (iii) a combination of (i) and (ii), and/or (c) with respect to any award shares held by the trustee for the benefit of the grantee, those award shares shall no longer be held on trust for or inure to the benefit of the grantee.

There are no arrangements for the Company or any of its subsidiaries to provide financial assistance to the Grantees to facilitate the purchase of Shares under the 2025 Share Incentive Plan.

## **REASONS FOR AND BENEFITS OF THE GRANT**

The purposes of the Grant are to (i) provide the Grantees with an opportunity to acquire proprietary interests in the Company; (ii) retain key personnel and high performers of the Group; (iii) provide the Grantees with additional incentives to achieve individual and corporate performance targets; and (iv) align the interests of the Grantees with those of the Shareholders by motivating them to enhance the value of the Company through equity ownership.

In particular, the Directors believe that, as a Service Provider Participant, Dr. Surmont's extensive experience in the healthcare and pharmaceutical industries will be invaluable to the Group in advancing the commercialization of its core pipeline for the treatment of CKM diseases. The Directors further consider that the grant of Options to Dr. Surmont will assist the Company in retaining him as its chief medical officer and will incentivize him to contribute to the long-term growth and development of the Group, which aligns with the purpose of the 2025 Share Incentive Plan.

## **LISTING RULES IMPLICATIONS**

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, none of the Grantees is (i) a Director, a chief executive, a substantial shareholder of the Company, or an associate of any of them; (ii) a participant with Options and Awards granted and to be granted exceeding the 1% individual limit under Rule 17.03D of the Listing Rules; or (iii) (other than Dr. Surmont) a related entity participant or service provider with Options and Awards granted and to be granted in any 12-month period exceeding 0.1% of the total issued Shares (excluding treasury Shares). The Grant will not be subject to approval by the Shareholders.

## **NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT**

As of the date of this announcement and immediately following the Grant, the number of Shares available for future grants under the Scheme Mandate Limit is 33,686,747 Shares, among which, the number of Shares available for future grants under the Service Provider Sublimit is 3,751,427 Shares.

## **DEFINITIONS**

|                             |                                                                                                                                              |
|-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| "2025 Share Incentive Plan" | the employee long term incentive plan adopted by the Company on June 27, 2025                                                                |
| "Award(s)"                  | the award(s) granted to a Grantee to subscribe for the same number of Shares at the purchase price pursuant to the 2025 Share Incentive Plan |
| "Board"                     | the board of directors of the Company                                                                                                        |
| "Company"                   | HighTide Therapeutics, Inc., a company incorporated under the laws of the Cayman Islands with limited liability on February 28, 2018         |
| "Director(s)"               | the director(s) of the Company, including all executive directors, non-executive directors and independent non-executive directors           |

|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “Employee Participant(s)”         | has the meaning ascribed thereto in Chapter 17 of the Listing Rules                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| “Grant Date”                      | September 1, 2026                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| “Grantee(s)”                      | eligible participant(s) under the 2025 Share Incentive Plan to be granted with Options and/or Awards pursuant to the corresponding scheme rules                                                                                                                                                                                                                                                                                                                                                                                     |
| “Group”                           | the Company and its subsidiaries                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| “HK\$”                            | Hong Kong dollars, the lawful currency of Hong Kong                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| “Hong Kong”                       | the Hong Kong Special Administrative Region of the People’s Republic of China                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| “Listing Rules”                   | the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time                                                                                                                                                                                                                                                                                                                                                                                                                   |
| “Option(s)”                       | a right granted to a Grantee to subscribe for the same number of Shares at the exercise price pursuant to the 2025 Share Incentive Plan                                                                                                                                                                                                                                                                                                                                                                                             |
| “Scheme Administrator”            | any person(s) authorized by the Board to have full authority to handle the matters in connection with the 2025 Share Incentive Plan                                                                                                                                                                                                                                                                                                                                                                                                 |
| “Scheme Mandate Limit”            | 36,033,946 Shares, being the maximum number of Shares underlying all Awards and Options which may be granted under the 2025 Share Incentive Plan and any other share incentive plans of the Company                                                                                                                                                                                                                                                                                                                                 |
| “Service Provider Participant(s)” | persons (natural person or corporate entity) who provide services to the Group on a continuing and recurring basis in the ordinary course of business of the Group which are in the interest of the long-term growth of the Group, including consultants or advisors who provide consultancy or advisory services to the Group in relation to research and development, production, marketing, strategic planning, finance, and administration, where the continuity and frequency of their services are akin to those of employees |
| “Service Provider Sublimit”       | 5,147,706 Shares, being the maximum number of Shares underlying all Awards and Options which may be granted to Service Provider Participants within the Scheme Mandate Limit                                                                                                                                                                                                                                                                                                                                                        |
| “Share(s)”                        | ordinary shares in the share capital of the Company with a par value of US\$0.0001 each                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| “Shareholder(s)”                  | holder(s) of the Share(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| “Stock Exchange”                  | The Stock Exchange of Hong Kong Limited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

“US\$” United States dollars, the lawful currency of the United States of America

“%” Per cent

By order of the Board  
**HighTide Therapeutics, Inc.**  
**Dr. LIU Liping**  
*Executive Director and Chief Executive Officer*

Hong Kong, September 1, 2026

*As of the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Dr. LI Jin, Mr. HUNG Tak Wai and Mr. CHEN Mingyu as independent non-executive Directors.*